A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Latest Information Update: 01 Jul 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications CNS cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms CheckMate 848
- Sponsors Bristol-Myers Squibb
- 01 Nov 2019 Planned number of patients changed from 800 to 1500.
- 30 Sep 2019 Planned End Date changed from 8 Sep 2023 to 31 Oct 2023.
- 30 Sep 2019 Planned primary completion date changed from 14 Mar 2021 to 15 Jun 2021.